AGENUS INC

AGEN Nasdaq CIK: 0001098972

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Accelerated filer
State of Incorporation DE
Business Address 3 FORBES ROAD, LEXINGTON, MA, 02421
Mailing Address 3 FORBES ROAD, LEXINGTON, MA, 02421
Phone 781-674-4410
Fiscal Year End 1231
EIN 061562417

Financial Overview

FY2024

$313.91M
Total Assets
-$160.33M
Stockholders' Equity
$178.67M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report February 9, 2026 View on SEC
4 Insider stock transaction report January 26, 2026 View on SEC
SCHEDULE 13D Beneficial ownership report (>5%) January 23, 2026 View on SEC
8-K Current report of material events January 16, 2026 View on SEC
3 Initial insider ownership report January 16, 2026 View on SEC
8-K Current report of material events January 14, 2026 View on SEC
4 Insider stock transaction report January 12, 2026 View on SEC
8-K Current report of material events January 8, 2026 View on SEC
4 Insider stock transaction report January 5, 2026 View on SEC
4 Insider stock transaction report January 5, 2026 View on SEC

Material Events

8-K Strategy Change January 16, 2026
High Impact
  • AGENUS received a $91 million cash infusion, significantly strengthening its balance sheet and extending its cash runway.
  • The company has become 'asset-light', sharpening its focus on high-value R&D and drug innovation.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.